Clinical Development
The safety, tolerability, and pharmacokinetic profile of CDP323 have been evaluated in 75 female and male healthy volunteers in three separate Phase 1 studies. CDP323 was well tolerated at oral doses up to 1000 mg given twice daily for 7 consecutive days with an adverse event profile comparable to that observed with placebo. There was no gender effect. The oral administration resulted in inhibition of VCAM-1 binding which could be maintained throughout a 12 or 24 hour dose interval at well tolerated doses
A Phase 2 study commenced in June 2007 in Europe and in the US. The study intends to enroll over 200 patients with relapsing MS who have failed earlier treatment with an interferon-beta and will compare two doses of the drug to placebo over a period of six months. The results are expected by the end of 2008.,
Read more about this topic: CDP323
Famous quotes containing the word development:
“Every new development for the last three centuries has brought men closer to a state of affairs in which absolutely nothing would be recognized in the whole world as possessing a claim to obedience except the authority of the State. The majority of people in Europe obey nothing else.”
—Simone Weil (1909–1943)